Testing ABO-101 for primary hyperoxaluria type 1
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called ABO-101 for people with primary hyperoxaluria type 1, a rare disease that causes high oxalate levels in urine. The study aims to see if ABO-101 can lower oxalate and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of primary hyperoxaluria type 1 (PH1).
- For part A, you must be between 18 and 64 years old. For part B, you must be between 6 and 18 years old.
- Your 24-hour urine oxalate level must be at least 0.7 mmol per day (adjusted for body size).
- Your kidney function (eGFR) must be 30 mL/min or higher.
- You must weigh 90 kg (about 198 pounds) or less.
- You cannot have had a liver, kidney, or combined transplant, be on dialysis, or have taken certain oxalate-lowering RNA treatments in the past 24 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores donated samples (like blood, urine, and tissue) from people with certain rare inherited kidney stone conditions. The goal is to build a resource for future research that could help improve diagnosis and treatment.
This trial tests an experimental drug called YOLT-203 for people with type 1 primary hyperoxaluria (PH1), a rare condition that causes high oxalate levels and can damage the kidneys. It aims to see if YOLT-203 can safely help manage the disease.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This trial tests a medication called stiripentol to see if it can lower oxalate levels in people with primary hyperoxaluria (types 1, 2, or 3). It may help prevent kidney stones and protect kidney function.
Hear when a new Primary Hyperoxaluria Type 1 (PH1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.